Matthew Laroe, MD
Endocrinology, Diabetes & Metabolism · Midlothian, VANPI 1598290454
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 355 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 39 manufacturers, the largest accounting for just 17.7% — the pattern of someone who eats at a lot of different presentations.
Across 355 payments — averaging $20.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Insulet Corporation$1K
- Novo Nordisk$1K
- Lilly USA, LLC$1K
- Amgen$502
- Abbott$296
- Boehringer Ingelheim$267
- plus $3K from 33 others
What the payments were for
- Food & beverage$7,357100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Insulet Corporation | 15 | $1,302 |
| Novo Nordisk | 83 | $1,084 |
| Lilly USA, LLC | 56 | $1,015 |
| Amgen(2 entities) | 31 | $502 |
| Abbott | 14 | $296 |
| Boehringer Ingelheim | 15 | $267 |
| Novartis | 10 | $230 |
| Sanofi-aventis U.S. LLC | 9 | $210 |
| IBSA Pharma Inc. | 10 | $206 |
| Amneal Pharmaceuticals LLC | 11 | $185 |
| Radius Health, Inc. | 7 | $173 |
| Xeris Pharmaceuticals, Inc. | 8 | $165 |
| Antares Pharma, Inc. | 8 | $157 |
| Pfizer | 8 | $157 |
| Tolmar, Inc. | 7 | $124 |
| Cequr Corporation | 3 | $97 |
| Dexcom, Inc. | 5 | $96 |
| AstraZeneca | 6 | $88 |
| BETA Bionics, Inc. | 5 | $86 |
| Halozyme Inc | 1 | $81 |
| Lifescan, Inc. | 4 | $81 |
| Tandem Diabetes Care, Inc. | 4 | $69 |
| Acella Pharmaceuticals, LLC | 1 | $67 |
| Bayer | 4 | $65 |
| Sequel Med Tech, LLC | 3 | $65 |
| Mannkind Corporation | 3 | $62 |
| Recordati_rare_diseases_inc. | 3 | $55 |
| Ascendis Pharma Endocrinology Inc | 3 | $54 |
| Esperion Therapeutics, Inc. | 3 | $52 |
| Soleno Therapeutics, Inc. | 2 | $41 |
| Boston Scientific | 2 | $40 |
| Corcept Therapeutics | 2 | $37 |
| AbbVie | 2 | $30 |
| Merck | 2 | $27 |
| Verity Pharmaceuticals Inc. | 1 | $25 |
| Amarin Pharma, Inc. | 1 | $21 |
| Astellas Pharma US Inc | 1 | $19 |
| Medtronic | 1 | $14 |
| Averitas Pharma Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Omnipod$864
How this compares
$7,357 in reported general payments places this provider in the 80th percentile of 223 endocrinology, diabetes & metabolism providers in Virginia.
See all endocrinology, diabetes & metabolism providers in Virginia →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 221 | $371,599 |
| JardianceEmpagliflozin | 198 | $254,071 |
| MounjaroTirzepatide | 119 | $229,218 |
| FarxigaDapagliflozin Propanediol | 61 | $74,283 |
| RybelsusSemaglutide | 37 | $73,824 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 56 | $66,174 |
| Tresiba Flextouch U-100Insulin Degludec | 72 | $62,249 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 41 | $57,944 |
| JanuviaSitagliptin Phosphate | 57 | $56,357 |
| TrulicityDulaglutide | 33 | $54,666 |
| Tresiba Flextouch U-200Insulin Degludec | 39 | $54,511 |
| Lyumjev Kwikpen U-100Insulin Lispro-Aabc | 13 | $39,879 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 37 | $35,015 |
| LyumjevInsulin Lispro-Aabc | 19 | $34,912 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 149 | $29,678 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus, Fiasp, Novolog | $1,084 | $480,067301 claims |
| Lilly USA, LLCMounjaro, Trulicity, Lyumjev, Humalog | $1,015 | $346,662246 claims |
| Boehringer IngelheimJardiance | $267 | $254,071198 claims |
| AstraZenecaFarxiga | $88 | $74,28361 claims |
| MerckJanuvia | $27 | $56,35757 claims |
| AmgenProlia | $502 | $21,27712 claims |
| AbbVieSynthroid | $30 | $13,169162 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $185 | $6,922600 claims |
| Sanofi-aventis U.S. LLCLantus | $210 | $6,59416 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 223 endocrinology, diabetes & metabolism providers in Virginia.
Other endocrinology, diabetes & metabolism in Midlothian
- Samamtha HudsonMidlothian$372K
- Ben PhillipsMidlothian$99K
- Meredith BergerMidlothian$32K
- Christina WagnerMidlothian$8K
- Farhad ZangenehSterling$1.2M
- James MulindaRoanoke$788K
- Jeffrey SicatGlen Allen$657K
- Dewey BaileyRoanoke$645K
- Domenica RubinoArlington$608K
- Elias SirajNorfolk$316K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.